ATE331801T1 - Defektive rekombinante adenoviren mit einem inaktivierten gen iv a 2 - Google Patents

Defektive rekombinante adenoviren mit einem inaktivierten gen iv a 2

Info

Publication number
ATE331801T1
ATE331801T1 AT95932050T AT95932050T ATE331801T1 AT E331801 T1 ATE331801 T1 AT E331801T1 AT 95932050 T AT95932050 T AT 95932050T AT 95932050 T AT95932050 T AT 95932050T AT E331801 T1 ATE331801 T1 AT E331801T1
Authority
AT
Austria
Prior art keywords
defective recombinant
recombinant adenoviruses
inactivated gene
adenoviruses
gene
Prior art date
Application number
AT95932050T
Other languages
English (en)
Inventor
Cecile Orsini
Michel Perricaudet
Emmanuelle Vigne
Patrice Yeh
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE331801T1 publication Critical patent/ATE331801T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/075—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C12N2710/10362—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT95932050T 1994-09-27 1995-09-22 Defektive rekombinante adenoviren mit einem inaktivierten gen iv a 2 ATE331801T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9411511A FR2724945B1 (fr) 1994-09-27 1994-09-27 Vecteurs viraux et utilisation en therapie genique

Publications (1)

Publication Number Publication Date
ATE331801T1 true ATE331801T1 (de) 2006-07-15

Family

ID=9467310

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95932050T ATE331801T1 (de) 1994-09-27 1995-09-22 Defektive rekombinante adenoviren mit einem inaktivierten gen iv a 2

Country Status (18)

Country Link
US (1) US6200798B1 (de)
EP (1) EP0783585B1 (de)
JP (1) JPH10506018A (de)
KR (1) KR100484441B1 (de)
AT (1) ATE331801T1 (de)
AU (1) AU712304B2 (de)
CA (1) CA2197904A1 (de)
DE (1) DE69535093T2 (de)
DK (1) DK0783585T3 (de)
ES (1) ES2268695T3 (de)
FI (1) FI971275A0 (de)
FR (1) FR2724945B1 (de)
IL (1) IL115432A (de)
MX (1) MX9701766A (de)
NO (1) NO319055B1 (de)
PT (1) PT783585E (de)
WO (1) WO1996010088A1 (de)
ZA (1) ZA958128B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960701988A (ko) * 1993-04-20 1996-03-28 윌리엄 에스. 로빈슨 세포내 감염원에 감염된 개체의 치료방법 및 치료물질(methods and materials for treatment of individuals infected with intracellular in-fectious agents)
CA2206683A1 (en) * 1994-12-12 1996-06-20 Genetic Therapy, Inc. Improved adenoviral vectors and producer cells
AUPN477695A0 (en) * 1995-08-14 1995-09-07 Commonwealth Scientific And Industrial Research Organisation Gene therapy
FR2753379B1 (fr) 1996-09-13 1998-10-30 Rhone Poulenc Rorer Sa Methode de traitement de la sclerose laterale amyotrophique
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
AU1288099A (en) 1997-10-30 1999-05-24 Cornell Research Foundation Inc. A method of inhibiting an immune response to a recombinant vector
CA2340276A1 (en) 1998-08-28 2000-03-09 Duke University Adenoviruses deleted in the iva2, 100k and/or preterminal protein sequences
FR2794771B1 (fr) 1999-06-11 2001-08-10 Aventis Pharma Sa Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
FR2799472B1 (fr) * 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
AUPR518501A0 (en) 2001-05-22 2001-06-14 Unisearch Limited Yin yang-1
WO2004018627A2 (en) * 2002-08-22 2004-03-04 Merck & Co., Inc. Methods for propagating adenovirus and virus produced thereby
ES2564823T3 (es) 2005-05-27 2016-03-29 Ospedale San Raffaele S.R.L. Vector génico que comprende miARN

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585362A (en) * 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
FR2707664B1 (fr) * 1993-07-13 1995-09-29 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.

Also Published As

Publication number Publication date
EP0783585A1 (de) 1997-07-16
IL115432A0 (en) 1996-01-31
WO1996010088A1 (fr) 1996-04-04
DE69535093D1 (de) 2006-08-10
JPH10506018A (ja) 1998-06-16
FI971275A7 (fi) 1997-03-26
FR2724945B1 (fr) 1996-12-27
ES2268695T3 (es) 2007-03-16
IL115432A (en) 2006-10-05
NO971247D0 (no) 1997-03-18
MX9701766A (es) 1997-06-28
AU712304B2 (en) 1999-11-04
NO319055B1 (no) 2005-06-13
CA2197904A1 (fr) 1996-04-04
AU3525095A (en) 1996-04-19
PT783585E (pt) 2006-11-30
FI971275L (fi) 1997-03-26
KR970706397A (ko) 1997-11-03
ZA958128B (en) 1996-04-24
NO971247L (no) 1997-03-18
DE69535093T2 (de) 2007-01-04
FR2724945A1 (fr) 1996-03-29
DK0783585T3 (da) 2006-10-23
KR100484441B1 (ko) 2006-01-27
EP0783585B1 (de) 2006-06-28
US6200798B1 (en) 2001-03-13
FI971275A0 (fi) 1997-03-26

Similar Documents

Publication Publication Date Title
FI971783A7 (fi) Adenoviruksia, joissa ei ole elinkykyisiä kontaminoivia partikkeleita, niiden valmistus ja käyttöjä
FI951138A7 (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
FI971613A7 (fi) Defektiivisiä adenoviruksia, jotka käsittävät terapeuttisen geenin ja immunoprotektiivisen geenin
ZA942778B (en) Recombinant viruses, and their preparation and use in gene therapy.
HUP9802217A3 (en) Recombinant mva virus, and the use thereof
DE69535093D1 (de) Defektive rekombinante adenoviren mit einem inaktivierten gen iv a 2
FR2712603B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
CA2204357A1 (en) Novel adenoviral vectors, packaging cell lines, recombinant adenoviruses and methods
DE69826661D1 (de) Antitumorale zusammenstellung von immunogene polypetiden mit veränderter zellokalisierung
BR9607583B1 (pt) plasmìdios procarióticos recombinantes.
FR2718150B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
FR2712602B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
FR2702152B1 (fr) Virus recombinants et leur utilisation en thérapie génique.
EP0747482A3 (de) Rekombinante Proteine des Hepatitis GB Virus ihre Verwendungen
FR2717495B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
IL112992A0 (en) Recombinant viruses, their preparation and their use in gene therapy
EP0536646A3 (en) Recombinant viruses, their application and production
FR2717823B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
ES296560U (es) Horno industrial calentado electricamente
FR2717497B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
MX9708877A (es) P62, sus variantes, las secuencias de acidos nucleicos que los codifican, y su utilizacion en terapia genica anti-cancerosa.
GB9315259D0 (en) Recombinant viruses

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0783585

Country of ref document: EP

REN Ceased due to non-payment of the annual fee